bosentan anhydrous has been researched along with vardenafil dihydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Gao, C; Liu, J; Wu, Y; Zhang, R; Zhao, M | 1 |
1 trial(s) available for bosentan anhydrous and vardenafil dihydrochloride
| Article | Year |
|---|---|
The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease: A protocol of randomized controlled trial.
Topics: Bosentan; Child; Drug Therapy, Combination; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Vardenafil Dihydrochloride | 2021 |
1 other study(ies) available for bosentan anhydrous and vardenafil dihydrochloride
| Article | Year |
|---|---|
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |